Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
PW Medtech Group Ltd. ( (HK:1358) ) has issued an announcement.
PW Medtech Group Ltd. announced the financial estimates for its subsidiary, Sichuan Ruijian Medical, for the first quarter of 2025. The revenue is expected to increase by 19.45% to 49.31% compared to the same period in 2024, while net profit attributable to shareholders is projected to decrease by 20.15% to 1.73%. This decline is primarily due to the implementation of a stock incentive plan for employees, which impacted the net profit figures.
More about PW Medtech Group Ltd.
PW Medtech Group Ltd., incorporated in the Cayman Islands, is primarily focused on investment holding. The company and its subsidiaries are engaged in the research and development, manufacturing, and sales of advanced infusion sets, intravenous cannula products, insulin needles, blood purification medical devices, and regenerative medical biomaterials in China.
YTD Price Performance: -6.36%
Average Trading Volume: 4,821
Technical Sentiment Signal: Sell
Current Market Cap: €184.7M
For an in-depth examination of 1358 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money